Gerona, Spain

Otto Halpern


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Otto Halpern

Introduction

Otto Halpern is a notable inventor based in Gerona, Spain. He has made significant contributions to the field of photodynamic therapy through his innovative work on porphycene compounds. With a total of 2 patents, Halpern's inventions are paving the way for advancements in medical treatments.

Latest Patents

Halpern's latest patents include novel 9-substituted porphycene compounds that are useful in photodynamic therapy. These compounds have the potential to enhance the effectiveness of treatments for various medical conditions. His work on 9-substituted porphycenes involves compounds characterized by the formula ##STR1##, wherein each R is --(CH.sub.2).sub.n --X, with n ranging from 1 to 10. In this formula, X is OR.sup.1, and R.sup.1 can be alkyl, aralkyl, or aryl, making them valuable as photosensitizer compounds in photodynamic therapy.

Career Highlights

Halpern is currently associated with Cytopharm, Inc., where he continues to develop innovative solutions in the field of photodynamic therapy. His work is instrumental in advancing the understanding and application of porphycene compounds in medical treatments.

Collaborations

Throughout his career, Halpern has collaborated with esteemed colleagues such as Emanuel Vogel and Martin Mueller. These partnerships have contributed to the success and impact of his inventions.

Conclusion

Otto Halpern's contributions to the field of photodynamic therapy through his innovative porphycene compounds highlight his role as a significant inventor. His work continues to inspire advancements in medical treatments, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…